Research today. Impact tomorrow.

25% Off the entire catalogue →

Same standards. Greater possibilities.

Research Use Only18+Not for Human ConsumptionReconstitution Materials Not Supplied
Peptide Database

Growth hormone & endocrine research

Tesa/IPA Protocol (Tesa-IPA): Research Overview

Vendor combination of tesamorelin and ipamorelin. No trials exist on the blend itself.

Also known as Tesamorelin / Ipamorelin blend · Tesa-IPA

Research use onlyStrongest evidence: early human studyReviewed
DatabaseReferences

What is Tesa/IPA Protocol?

The Tesa/IPA blend combines two complementary growth hormone secretagogues: Tesamorelin (a GHRH analog that stimulates GH release from the pituitary) and Ipamorelin (a selective ghrelin mimetic/GHRP that amplifies GH pulses). This combination addresses both the GHRH and GHRP pathways for synergistic GH release.

What is Tesa/IPA Protocol researched for?

  • Tesamorelin has demonstrated fat reduction in clinical trials; synergy with Ipamorelin may enhance effects.
  • Tesamorelin specifically reduces visceral adipose tissue (FDA-approved indication).
  • Enhanced GH promotes protein synthesis and lean tissue preservation.
  • GH secretagogues often improve deep sleep quality.
  • Enhanced GH supports tissue repair and recovery from exercise.
  • Restoring more youthful GH levels may provide anti-aging benefits.
  • Tesamorelin has shown improvements in lipid parameters in studies.
  • Increased GH leads to increased IGF-1 production.

How does Tesa/IPA Protocol work?

The blend leverages two distinct GH-releasing pathways: Tesamorelin is a synthetic GHRH analog that directly stimulates growth hormone-releasing hormone receptors on pituitary somatotrophs, triggering GH synthesis and secretion in a pulsatile, physiological manner.

Reported targets: GHS-R1a, ghrelin receptor

References

  1. Metabolic effects of a growth hormone-releasing factor in patients with HIV

    Falutz J, Allas S, Blot K, et al. · The New England journal of medicine · 2007

    Landmark RCT in 412 HIV patients: tesamorelin 2 mg daily for 26 weeks reduced visceral fat by 10.9% vs 0.6% placebo, improved lipid profiles with no change in subcutaneous fat.

    Early human study · PMID 18057338

  2. Ipamorelin, the first selective growth hormone secretagogue

    Raun K, Hansen BS, Johansen NL, et al. · European journal of endocrinology · 1998

    Ipamorelin is the first GHRP-receptor agonist with selectivity for GH release similar to GHRH; does not release ACTH or cortisol even at doses over 200-fold the ED50 for GH.

    PMID 9849822

  3. GHRH + GHRP Synergy Endocrine Reviews Combining GHRH and GHRP pathways produces synergistic GH release greater than either agent alone, driven by independent receptor mechanisms on pituitary somatotrophs.

  4. Combining GHRH and GHRP pathways produces synergistic GH release greater than either agent alone, driven by independent receptor mechanisms on pituitary somatotrophs.

  5. No Published Studies on Tesa/IPA Combination N/A

    2024

    No clinical trials have evaluated the specific tesamorelin + ipamorelin blend; synergy is inferred from GHRH/GHRP pharmacology and individual component data.